Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease.
about
Systems biology of polycystic kidney disease: a critical reviewA distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapyUrinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyDangers within: DAMP responses to damage and cell death in kidney disease.Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaA metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney diseaseProteomic analysis of urinary upper gastrointestinal cancer markers.Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.An empirical assessment of validation practices for molecular classifiersFibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).Recent developments in proteomic methods and disease biomarkers.Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.Renal CD14 expression correlates with the progression of cystic kidney diseaseUrinary proteomics for early diagnosis in diabetic nephropathy.Urine proteome of autosomal dominant polycystic kidney disease patients.Urine proteomes of healthy aging humans reveal extracellular matrix (ECM) alterations and immune system dysfunction.Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline.CE-MS in biomarker discovery, validation, and clinical application.Clinical application of urinary proteomics/peptidomics.Growing trend of CE at the omics level: the frontier of systems biology--an update.Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics.Proteomic biomarkers in kidney disease: issues in development and implementation.Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.Body fluid peptide and protein signatures in diabetic kidney diseases.Uromodulin: from physiology to rare and complex kidney disorders.Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.Diagnostic Evaluation as a Biomarker in Patients with ADPKD.Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine.Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine.A stable panel comprising 18 urinary proteins in the human healthy population.Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS
P2860
Q28081359-F4CC5C9E-7F39-4C2C-8B77-7ACFE95092BAQ28478586-9FF77B79-F1F8-4A5F-A9D0-8F84C62C65ABQ28484968-87809304-A71A-4EA1-AD56-548721F860E5Q30380000-82D33513-8BA9-46C6-A939-FB235708087CQ33735287-B603AB13-414B-4981-B659-3EEB93800398Q33784024-55AB699C-D000-4D61-BC97-F6EDCC1CAD27Q33888474-680BBB82-B739-4EDA-BDF5-6834330FFB69Q34725022-4E7B8038-FDAC-43A8-A664-C4B51834119AQ34933977-A4521841-50E6-4983-90D2-D3D5B6B00309Q35194509-53A29BE3-6490-4748-9240-205724E0D0E4Q35197167-98B84DB0-268A-4360-8C16-599CDBA77071Q35559202-8CFD764A-ABCD-46C2-ADD3-A46AACBA8CCCQ35669323-C3D59830-C4B7-48DE-BB3F-1C24B4E8FE9CQ35870104-B878FDAF-BDC9-48FD-ABBE-B292CD3B42ADQ36172922-3D25278C-F421-4750-8499-73B1897D7EAAQ36410737-4E578149-5F64-4558-887A-9F3794279235Q36715758-C9181D26-D799-4EF0-8B94-352A572E8AC3Q37471129-FFDD95E2-0344-4D30-A4B1-667276827851Q37529560-10227582-1239-453F-BCB3-B200E0D775E4Q37833587-28579156-20D8-4180-963C-7BE7533C514DQ37945790-A5EECE4E-F069-4353-93AC-1E6C1E3A78C8Q37964549-890E63A6-40E3-4FAD-B0E5-57A051C1AF2DQ38030726-15CA9F8C-F9E0-4A39-AE88-016D9193EC23Q38340351-C35D7EB8-5E96-4D39-98CA-9923C00ECAF2Q38341211-72F3992B-06F0-471D-8B40-7768848E4921Q38384848-7AE767A5-9187-40E6-9385-E34E0C7D7C35Q38553924-8DE4281D-F4C5-401A-9B91-A0A24F332FD6Q38638219-50A9AF76-0E0F-4B7E-A615-004963AB1419Q38906256-8C5C3046-BCA2-4630-8664-90545F6CA3EBQ38978474-E82F0784-E230-4A11-934B-88893A6F0BFAQ41142978-9D1B58B5-38BA-420B-9720-F5A88B8110D3Q50708333-ADFED403-4328-4112-B388-B85F182EE169Q51344954-7BADE4C1-12CE-445F-8EB3-BE47B170D562Q52850208-17F2667F-2976-4CE5-9922-D8C9063D094DQ57711927-239EA5D1-1D77-496B-81CA-92F0F8DFBE53
P2860
Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Identification of a unique uri ...... ant polycystic kidney disease.
@en
Identification of a unique uri ...... ant polycystic kidney disease.
@nl
type
label
Identification of a unique uri ...... ant polycystic kidney disease.
@en
Identification of a unique uri ...... ant polycystic kidney disease.
@nl
prefLabel
Identification of a unique uri ...... ant polycystic kidney disease.
@en
Identification of a unique uri ...... ant polycystic kidney disease.
@nl
P2093
P921
P356
P1433
P1476
Identification of a unique uri ...... ant polycystic kidney disease.
@en
P2093
Andreas D Kistler
Andreas L Serra
Diane Poster
Mohammed Dakna
Rudolf P Wüthrich
P2888
P356
10.1038/KI.2009.93
P407
P577
2009-04-01T00:00:00Z